What the Study Found (In Plain English)
Published in Nederlands tijdschrift voor geneeskunde (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: To investigate whether active surveillance is non-inferior to standard surgery for patients with a complete clinical response (CCR) after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer. Key clinical takeaway: Active surveillance is non-inferior to standard surgery after two years for patients with CCR post-nCRT. Further follow-up is needed to confirm long-term efficacy and safety.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Nederlands tijdschrift voor geneeskunde, 2025-11-25; Phase III Randomized Trial; Rigor 82/100): Active surveillance is non-inferior to standard surgery after two years for patients with CCR post-nCRT. Further follow-up is needed to confirm long-term efficacy and safety.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.